The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2020
Filed:
May. 23, 2017
Applicant:
Roche Glycart Ag, Schlieren, CH;
Inventors:
Harald Duerr, Starnberg, DE;
Frank Herting, Penzberg, DE;
Christian Klein, Bonstetten, CH;
Joerg Thomas Regula, Munich, DE;
Matthias Rueth, Penzberg, DE;
Kay-Gunnar Stubenrauch, Penzberg, DE;
Assignee:
Roche Glycart AG, Schlieren, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/22 (2006.01); A61K 39/00 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61P 27/02 (2018.01); A61P 27/06 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.